Biotech stocks are rocking even in OTC markets by shooting significant points. Today Rasna Therapeutics (OTC: RASP) soars by 17 fold on as little as 3k shares of the daily volume. Rasna shares have been penny since the RASP officially offered many years ago.
The main focus of Rasna is to develop viable programs to neutralize leukemia while covering other immune and oncological issues of patients. Therefore, Rasna spends a lot of funds and still can’t have positive EPS, unlike Regeneron.
RASP shares have been trending at the beginning of August while losing significant points. However, today’s skyrocketing event RASP is reviving back.
Finance and Tech Contributor